To see the other types of publications on this topic, follow the link: Nineteen seventy-five, A.D.
Journal articles on the topic 'Nineteen seventy-five, A.D'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Nineteen seventy-five, A.D.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Gill, K. S., E. L. Lubbers, B. S. Gill, W. J. Raupp, and T. S. Cox. "A genetic linkage map of Triticum tauschii (DD) and its relationship to the D genome of bread wheat (AABBDD)." Genome 34, no. 3 (June 1, 1991): 362–74. http://dx.doi.org/10.1139/g91-058.
Full textAbstract:
One hundred and seventy-eight loci have been mapped in Triticum tauschii (Coss.) Schmal. (2n = 14, DD) and Triticum aestivum L. em. Thell. (2n = 42, AABBDD). Thirty-five loci were mapped by aneuploid analysis in T. aestivum. One hundred and fifty-two loci, including 143 restriction fragment length polymorphisms (RFLPs), 8 proteins, and 1 leaf rust resistance gene, were mapped in an F2 population (60 plants) of T. tauschii. One hundred and twenty-seven loci were placed in linkage groups belonging to seven D-genome chromosomes of T. tauschii. The source of the probes was a PstI genomic library of T. tauschii, which gave 13% single-low copy clones. Four restriction endonucleases (DraI, EcoRI, EcoRV, HindIII) gave 75% polymorphism between the two parents. Nineteen clones detected multiloci ranging from two to nine in number. Deletions–insertions and point mutations were equally important for generating RFLPs. A hypervariable sequence was identified, which may have potential use in varietal fingerprinting. One marker was found to be linked to a rust-resistance gene. The map will be useful for determining genetic relationships in the Triticeae and for tagging genes of economic importance.Key words: restriction fragment length polymorphism, Triticum aestivum, leaf rust, isozymes, Aegilops squarrosa.
2
Schalock, Robert L., Brent Wolzen, Irv Ross, Barb Elliott, Ginger Werbel, and Kathy Peterson. "Post-Secondary Community Placement of Handicapped Students: A Five-Year Follow-Up." Learning Disability Quarterly 9, no. 4 (November 1986): 295–303. http://dx.doi.org/10.2307/1510383.
Full textAbstract:
This article presents the results of an evaluation of the employment and living status of 108 moderately to severely handicapped individuals who had graduated during a five-year period (1979–1983) from rural schools employing a community-based job exploration and training model. Nineteen predictor variables including student characteristics, school variables, and county characteristics were statistically related to nine employment-related outcome variables. The results showed that (a) 61% of the graduates were working competitively; (b) 22% were living independently; (c) the specific-learning disabled student was more likely to be employed, live independently and be self-sufficient than the educable mentally handicapped or the student with mental retardation; (d) students whose families were moderately to highly involved with the students' programs were more successful on the employment-related outcome variables; and (e) significant predictors included both student characteristics and environmental variables. Implications are discussed relative to the current emphasis on post-graduation job placement, program accountability, training in the natural environment and support systems.
3
Alfaham, Mazin, Stuart Woodhead, Gunilla Pask, and David Davies. "Vitamin D deficiency: a concern in pregnant Asian women." British Journal of Nutrition 73, no. 6 (June 1995): 881–87. http://dx.doi.org/10.1079/bjn19950093.
Full textAbstract:
Vitamin D status of Asian mothers in Cardiff was investigated during early pregnancy and at the time of the birth of their babies, using serum parathyroid hormone (PTH). Median values in Asian (n 32) and Caucasian (n 63) mothers in early pregnancy were 1·56 and 0·81 pmol/1 respectively. PTH levels from a separate sample of nineteen Asian and twenty-five Caucasian mothers at the time of birth were 3·0 and 2·20 pmol/1 respectively. Altogether twelve Asian and two Caucasian women had elevated PTH. All Asian women who had high PTH values also had a very low serum 25-hydroxycholecalciferol level (25OHD). All samples were taken from women with no significant medical history and normal obstetric history. These findings suggest that subclinical vitamin D deficiency is still a cause for concern in Asian women. More active measures need to be taken to implement current recommendations to improve their vitamin D intake in pregnancy.
4
Chang, Sue-Joan, Li-Ju Hsiao, Yi-Chun Lee, and Shou-Ying Hsuen. "Vitamin B6 status assessment in relation to dietary intake in high school students aged 16–18 years." British Journal of Nutrition 97, no. 4 (March 9, 2007): 764–69. http://dx.doi.org/10.1017/s0007114507665167.
Full textAbstract:
The vitamin B6 status of high school students and its relationship with dietary intake were investigated in this cross-sectional study by face-to-face interview. A total of 157 healthy students aged 16–18 years (eighty-three boys and seventy-four girls) were randomly recruited from two out of nineteen senior high schools in Tainan, Taiwan. Vitamin B6 intakes were calculated from three 24-h dietary records. Direct and indirect vitamin B6 status indicators were measured in plasma, erythrocytes and urine. The anthropometric data, being similar to those of the first Nutrition and Health Survey in Taiwan (1993–1996), showed the normal growth and development of these students. All students except one girl (28·7 nmol/l) had plasma pyridoxal-5′-phosphate (PLP) levels >35 nmol/l, indicating an adequate vitamin B6 status. The mean dietary vitamin B6 intakes of boys and girls were 1·04 (sd 0·29) and 0·96 (sd 0·27) mg/d, respectively. Vitamin B6 status indicators, including plasma PLP, erythrocyte alanine aminotransferase activity coefficient (EALT-AC), aspartate aminotransferase activity coefficient (EAST-AC) and urinary 4-pyridoxic acid (4-PA), were correlated with vitamin B6 intake. Students with adequate values of plasma PLP (>35 nmol/l), EALT-AC ( < 1·25), EAST-AC ( < 1·8) and urinary 4-PA (>3·0 μmol/d) had median intakes of 1·08 and 1·01 mg/d, respectively, for boys and girls. This study suggests that vitamin B6 requirements for boys and girls aged 16–18 years were approximately 1·1 and 1·0 mg/d, respectively.
5
Ibrahimovic, Mirela, Elizabeth Franzmann, Alison M. Mondul, Katherine M. Weh, Connor Howard, Jennifer J. Hu, W. Jarrard Goodwin, and Laura A. Kresty. "Disparities in Head and Neck Cancer: A Case for Chemoprevention with Vitamin D." Nutrients 12, no. 9 (August 29, 2020): 2638. http://dx.doi.org/10.3390/nu12092638.
Full textAbstract:
Blacks experience disproportionate head and neck cancer (HNC) recurrence and mortality compared to Whites. Overall, vitamin D status is inversely associated to HNC pointing to a potential protective linkage. Although hypovitaminosis D in Blacks is well documented it has not been investigated in Black HNC patients. Thus, we conducted a prospective pilot study accessing vitamin D status in newly diagnosed HNC patients stratified by race and conducted in vitro studies to investigate mechanisms associated with potential cancer inhibitory effects of vitamin D. Outcome measures included circulating levels of vitamin D, related nutrients, and risk factor characterization as well as dietary and supplemental estimates. Vitamin D-based in vitro assays utilized proteome and microRNA (miR) profiling. Nineteen patients were enrolled, mean circulating vitamin D levels were significantly reduced in Black compared to White HNC patients, 27.3 and 20.0 ng/mL, respectively. Whites also supplemented vitamin D more frequently than Blacks who had non-significantly higher vitamin D from dietary sources. Vitamin D treatment of HNC cell lines revealed five significantly altered miRs regulating genes targeting multiple pathways in cancer based on enrichment analysis (i.e., negative regulation of cell proliferation, angiogenesis, chemokine, MAPK, and WNT signaling). Vitamin D further altered proteins involved in cancer progression, metastasis and survival supporting a potential role for vitamin D in targeted cancer prevention.
6
Baselga, J., D. Rischin, M. Ranson, H. Calvert, E. Raymond, D. G. Kieback, S. B. Kaye, et al. "Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types." Journal of Clinical Oncology 20, no. 21 (November 1, 2002): 4292–302. http://dx.doi.org/10.1200/jco.2002.03.100.
Full textAbstract:
PURPOSE: To establish the safety and tolerability of ZD1839 (Iressa), a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, and to explore its pharmacokinetic and pharmacodynamic effects in patients with selected solid tumor types. PATIENTS AND METHODS: This was a phase I dose-escalating trial of oral ZD1839 150 mg/d to a maximum of 1,000 mg/d given once daily for at least 28 days. Patients with either advanced non–small-cell lung, ovarian, head and neck, prostate, or colorectal cancer were recruited. RESULTS: Eighty-eight patients received ZD1839 (150 to 1,000 mg/d). At 1,000 mg/d, five of 12 patients experienced dose-limiting toxicity (grade 3 diarrhea [four patients] and grade 3 somnolence [one patient]). The most frequent drug-related adverse events (AEs) were acne-like rash (64%) and diarrhea (47%), which were generally mild (grade 1/2) and reversible on cessation of treatment. No change in ZD1839 safety profile was observed with prolonged administration. Pharmacokinetic analysis showed steady-state exposure to ZD1839 in 98% of patients by day 7. Nineteen patients had stable disease and received ZD1839 for ≥ 3 months; seven of these patients remained on study drug for ≥ 6 months. Serial skin biopsies taken before treatment and at approximately day 28 revealed changes indicative of inhibition of the EGFR signaling pathway. CONCLUSION: ZD1839 was generally well tolerated, with manageable and reversible AEs at doses up to 600 mg/d and dose-limiting toxicity observed at 1,000 mg/d. ZD1839 treatment resulted in clinically meaningful disease stabilization across a range of tumor types and doses. Pharmacodynamic changes in skin confirmed inhibition of EGFR signaling, which was predicted from the mode of action of ZD1839.
7
Fynes, Jamie M., and Leslee A. Fisher. "Is Authenticity and Integrity Possible for Sexual Minority Athletes? Lesbian Student-Athlete Experiences of U.S. NCAA Division I Sport." Women in Sport and Physical Activity Journal 24, no. 1 (April 2016): 60–69. http://dx.doi.org/10.1123/wspaj.2014-0055.
Full textAbstract:
The purpose of this study was to explore the congruence of identity in 10 former U.S. NCAA Division I (DI) lesbian student-athletes using a semistructured personal identity interview guide (adapted from Fisher, 1993) and Consensual Qualitative Research (CQR) (Hill, 2012; Hill, Knox, Thompson, Williams, Hess, & Ladany, 2005). Five domains, nineteen categories, and related core ideas were found in the transcribed interviews. The five domains were: (a) stereotypes and perceptions of female athletes; (b) stereotypes and perceptions of lesbians and lesbian athletes; (c) climate for LGBT athletes; (d) negotiating identities; and (e) recommendations for college campuses. The main goal of the current study was to determine whether lesbian athletes felt comfortable being who they are in the context of U.S. DI sport. Recommendations for how applied sport psychology consultants, coaches, and administrators, all of whom play an important role in athletes’ collegiate sport experience, could change the structure of U.S. universities to help lesbian student-athletes become more comfortable are given.
8
Gavala, Alexandra, Konstantinos Makris, Anna Korompeli, and Pavlos Myrianthefs. "Evaluation of Bone Metabolism in Critically Ill Patients Using CTx and PINP." BioMed Research International 2016 (2016): 1–9. http://dx.doi.org/10.1155/2016/1951707.
Full textAbstract:
Background. Prolonged immobilization, nutritional and vitamin D deficiency, and specific drug administration may lead to significant bone resorption. Methods and Patients. We prospectively evaluated critically ill patients admitted to the ICU for at least 10 days. Demographics, APACHE II, SOFA scores, length of stay (LOS), and drug administration were recorded. Blood collections were performed at baseline and on a weekly basis for five consecutive weeks. Serum levels of PINP, β-CTx, iPTH, and 25(OH)vitamin D were measured at each time-point. Results. We enrolled 28 patients of mean age 67.4 ± 2.3 years, mean APACHE II 22.2 ± 0.9, SOFA 10.1 ± 0.6, and LOS 31.6 ± 5.7 days. Nineteen patients were receiving low molecular weight heparin, 17 nor-epinephrine and low dose hydrocortisone, 18 transfusions, and 3 phenytoin. 25(OH)vitamin D serum levels were very low in all patients at all time-points; iPTH serum levels were increased at baseline tending to normalize on 5th week; β-CTx serum levels were significantly increased compared to baseline on 2nd week (peak values), whereas PINP levels were increased significantly after the 4th week. Conclusions. Our data show that critically ill patients had a pattern of hypovitaminosis D, increased iPTH, hypocalcaemia, and BTMs compatible with altered bone metabolism.
9
Shill, Lincon Chandra, Nafisa Habib Purba, Marjia Sultana, Towhid Hasan, Mahmudur Rahman, and Nahid Sultana. "An update on osteoporosis research: effect of calcium plus vitamin D supplementation." International Journal Of Community Medicine And Public Health 6, no. 9 (August 27, 2019): 4120. http://dx.doi.org/10.18203/2394-6040.ijcmph20194028.
Full textAbstract:
Osteoporosis is the most common systemic skeletal disease characterized by increased bone fragility. There lies an incongruity among research regarding combined supplementation of calcium (Ca) plus vitamin D and loss of bone health. Hence, the present review is aimed to highlight the current development of osteoporosis research and try to solve the inconsistency among the present knowledge. Electronic databases like PubMed, Cochrane Library, and EMBASE were searched from their inception to December 2018 using terms “calcium,” “vitamin D,” and “osteoporosis.” A systemic approach was followed to reach a final of 23 studies assessing the synergetic effect of calcium and vitamin D on osteoporosis and fractures risk. Among the included studies, nineteen have revealed that calcium and vitamin D decrease bone resorption, reduce the incidence of fractures, increase bone mineral density (BMD) and overall bone health. However, no significant osteogenic response was reported in five trials after supplementation with calcium and vitamin D together. Osteoporosis results in a reduced quality of life, increased disability-adjusted life span, and big economic burden to health care systems of countries. Early diagnosis before the occurrence of fractures and by assessing BMD and with early treatment, osteoporosis can be prevented. It is not entirely possible to draw a conclusion regarding beneficial effects of calcium plus vitamin D supplementation; future research based on the fundamentals of bone biology focusing on molecular genetics, and influencing factors of the acquisition of bone mass during growth and bone loss can alleviate present controversies.
10
Cunningham, Kay, M. J. Gibney, A. Kelly, J. Kevany, and M. Mulcahy. "Nutrient intakes in long-stay mentally handicapped persons." British Journal of Nutrition 64, no. 1 (July 1990): 3–11. http://dx.doi.org/10.1079/bjn19900004.
Full textAbstract:
A study of the dietary intake of 115 male and 217 female mentally handicapped persons aged 15–64 years in five long-stay institutions was carried out using a semi-weighed technique over 4 d. Nineteen per cent of males and 5% of females were classified as being underweight and 15% of males and 27% of females were classified as being obese. The average daily intakes of nutrients were: energy 8.8 MJ, protein 92 g, carbohydrate 218 g, fat 101 g, dietary fibre 18 g, calcium 1024 mg, iron 12.5 mg, vitamin B6 1.4 mg, vitamin B12 10.8 μg, ascorbic acid 68 mg. The distribution of energy between protein, carbohydrate and fat was 18, 39 and 43% respectively. Energy intakes were not related to ambulatory status, degree of mental handicap, the level of drug usage or body mass index. Energy intakes varied significantly between hospitals and between the sexes.
11
Vestøl, Irene, Jonas Debesay, and Astrid Bergland. "Mobility—A Bridge to Sense of Coherence in Everyday Life: Older Patients’ Experiences of Participation in an Exercise Program During the First 3 Weeks After Hip Fracture Surgery." Qualitative Health Research 31, no. 10 (April 30, 2021): 1823–32. http://dx.doi.org/10.1177/10497323211008848.
Full textAbstract:
Our aim with this article was to explore the experiences of older people who participated in the evidence-based High-Intensity Functional Exercise (HIFE) Program during the first 3 weeks of rehabilitation after hip fracture surgery. Nineteen older people participated in the study. Data were analyzed using systematic text condensation. One overarching theme “Exercise is the key for regaining mobility and a sense of coherence (SOC) in everyday life” emerged from the analysis in addition to these five themes: (a) understanding the existential importance of mobility; (b) maintaining a positive self-image by regaining mobility; (c) regaining one’s old life and independence in everyday living; (d) maintaining interpersonal relationships through mobility; and (e) creating positive emotions by being able to move. The findings highlight the importance of exercise as a strategy for regaining mobility, illustrated by the essential role it played in the participants’ lives after suffering a hip fracture.
12
Bailey, Angela L., P. M. Finglas, A. J. A. Wright, and Susan Southon. "Thiamin intake, erythrocyte transketolase (EC 2.2.1.1) activity and total erythrocyte thiamin in adolescents." British Journal of Nutrition 72, no. 1 (July 1994): 111–25. http://dx.doi.org/10.1079/bjn19940014.
Full textAbstract:
The relationships between thiamin intake, erythrocyte transketolase (EC 2.2.1.1) activity coefficient (ETK-AC) and total erythrocyte thiamin were investigated in a group of adolescents (13 to 14 years old; nineteen boys, thirty-five girls). Thiamin intakes were calculated from 7 d weighed records, using food composition tables, and compared with those obtained by direct analysis of duplicate diets. Average 7 d calculated thiamin intakes were significantly lower than analysed intakes for both sexes. On an individual basis, calculated intakes ranged from 30 to 143 % of corresponding analysed values. Analysed and calculated intakes were significantly correlated when expressed as mg/d; however, when expressed in terms of energy intake, the correlation was significant for males only. Thiamin intake appeared largely adequate when compared with current UK dietary recommendations (Department of Health, 1991), but the limitations of such comparisons are considered. The major food groups contributing to thiamin intake were examined and showed breakfast cereals to contribute more than 25% of dietary thiamin. A proportion of the subjects had ETK-AC values in ranges usually associated with marginal or severe thiamin deficiency. There was, however, no statistically significant relationship between erythrocyte thiamin and basal or stimulated transketolase activity, or between thiamin intake and either of the methods used to assess status. The need to re-evaluate indices of thiamin status is discussed.
13
Sanchez-Castillo, Claudia P., David Grubb, Maria De Lourdes Solano, Michael F. Franklin, and W. Philip T. James. "Non-starch polysaccharide intakes in Mexican villagers and residents of Mexico City." British Journal of Nutrition 77, no. 3 (March 1997): 345–57. http://dx.doi.org/10.1079/bjn19970037.
Full textAbstract:
A study was performed in a rural Mexican community and in Mexico City to investigate possible differences in non-starch polysaccharide (NSP) intakes. One hundred and fourteen women (fifty-five rural and fitty-nine urban) and forty-three men (twenty-four rural and nineteen urban) completed 24 h recall questionnaires for three consecutive days with NSP intakes being estimated from a specially prepared set of new food composition tables. Potential underestimation of intakes was assessed by estimating individual BMR and dividing the estimated energy intakes by BMR to give a ratio. Excluding severe underrecording (ratio < 1·01) suggested NSP intakes of 21·8 and 17·3 g/d in rural men and women and 17·7 and 15·6 g/d in urban men and women respectively. NSP sources differed, with a marked fall in intake from pulses in the urban areas but a compensatory increase of tortilla intakes and a rise in NSP-rich fruit consumption. Both soluble- and insoluble-NSP intakes were higher in rural areas. NSP intakes scaled by probable energy intakes of moderately active adults in developing countries suggest that NSP intakes in Mexico are similar to adjusted values in Africa, i.e. 26·9 g/d in Mexico v. 28·5 g/d in Africa in rural men and 22·9 v. 21·0 g/d respectively in rural women. The NSP: energy density ratio (g/MJ) of the rural diet conformed with the World Health Organization (1990) goal. Data available on urban and rural communities for three countries showed that in each case the intake of NSP was lowest in the urban community.
14
Souza, N. F., and M. H. M. A. Larsson. "Frequency of canine heartworm disease (D. immitis) in some regions of São Paulo State using a circulating antigen indicator test." Arquivo Brasileiro de Medicina Veterinária e Zootecnia 53, no. 3 (June 2001): 321–25. http://dx.doi.org/10.1590/s0102-09352001000300009.
Full textAbstract:
The frequency of canine heartworm disease was determined in 310 dogs (158 males and 152 females) from São Paulo city (154) and several towns along the São Paulo state coast (156). The survey was carried out through the Knott's technique (direct presence of microfilariae in the blood) and ELISA for soluble circulating antigen detection. Twenty five (8.0%) samples were positive to D. immitis using both methods being 6 dogs (3.9%) from the city and 19 (12.2%) from the coastal area. Nineteen dogs (6.1%) were positive to the Knott's technique (4 from the city and 15 from the coastal area) and 12 dogs (3.9%) to the ELISA (4 from the city and 8 from the coastal area); six dogs (1.9%) were positive for both methods being two from the city and four from the coastal area. The frequency of positive dogs by the Knott's technique in the coastal area was higher than that in São Paulo city (P<0.05), but equivalent frequency was found in dogs from both areas when the ELISA test was used. Higher number of dogs with a patent infection (microfilaremic) was found than those with occult infection (amicrofilaremic). This survey has shown that the dogs were not infected with high frequency probably because the studied areas were not hiperenzootic endemic (higher than 10% of frequency).
15
Graham, M. L., J. E. Herndon, J. R. Casey, S. Chaffee, G. H. Ciocci, J. P. Krischer, J. Kurtzberg, et al. "High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors." Journal of Clinical Oncology 15, no. 5 (May 1997): 1814–23. http://dx.doi.org/10.1200/jco.1997.15.5.1814.
Full textAbstract:
PURPOSE We treated 49 patients with recurrent or poor-prognosis CNS malignancies with high-dose chemotherapy regimens followed by autologous marrow rescue with or without peripheral-blood stem-cell augmentation to determine the toxicity of and event-free survival after these regimens. PATIENTS AND METHODS Nineteen patients had medulloblastomas, 12 had glial tumors, seven had pineoblastomas, five had ependymomas, three had primitive neuroectodermal tumors, two had germ cell tumors, and one had fibrosarcoma. Thirty-seven received chemotherapy with cyclophosphamide 1.5 g/m2 daily x 4 and melphalan 25 to 60 mg/m2 daily x 3. Nine received busulfan 37.5 mg/m2 every 6 hours x 16 and melphalan 180 mg/m2 (n = 7) or 140 mg/m2 (n = 2). Three received carboplatin 700 mg/m2/d on days -7, -5, and -3 and etoposide 500 mg/m2/d on days -6, -4, and -2. All patients received standard supportive care. RESULTS Eighteen of 49 patients survive event-free 22+ to 55+ months (median, 33+) after transplantation, including nine of 16 treated before recurrence and nine of 33 treated after recurrence. There was one transplant-related death from pulmonary aspergillosis. Of five patients assessable for disease response, one had a partial remission (2 months), one has had stable disease (55+ months), and three showed progression 2, 5, and 8 months after transplantation. CONCLUSION The toxicity of these regimens was tolerable. Certain patients with high-risk CNS malignancies may benefit from such a treatment approach. Subsequent trials should attempt to determine which patients are most likely to benefit from high-dose chemotherapy with autologous stem-cell rescue.
16
Mahoney, D. H., D. Strother, B. Camitta, T. Bowen, T. Ghim, T. Pick, D. Wall, L. Yu, J. J. Shuster, and H. Friedman. "High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot pediatric oncology group study." Journal of Clinical Oncology 14, no. 2 (February 1996): 382–88. http://dx.doi.org/10.1200/jco.1996.14.2.382.
Full textAbstract:
PURPOSE To determine the maximum-tolerated dose of cyclophosphamide (CTX) when administered sequentially with melphalan 60 mg/m2/d for 3 days, followed by autologous bone marrow rescue (ABMR), in children with recurrent or progressive malignant brain tumors, and to make preliminary observations on efficacy. PATIENTS AND METHODS Nineteen patients between the ages of 2 and 21 years were enrolled and 18 were assessable for effects of therapy. CTX was administered to seven patients at 750 mg/m2/d for 4 days, to five patients at 975 mg/m2/d, to three patients at 1,200 mg/m2/d, and to three patients at 1,500 mg/m2/d. All patients received ABMR. Granulocyte-macrophage colony-stimulating factor (GM-CSF) was used in 15 patients. Toxicity, response to therapy, time to progression, and survival and monitored. RESULTS The median time to a granulocyte count more than 500/dL was 19 days (range, 11 to 39), and for a platelet count more than 50,000/dL was 33 days (range, 16 to 60). Four heavily pretreated patients (22%) died of transplant-related complications. No dose-limiting, non-hematologic toxicities were defined for the study. Seven of 18 patients (39%) had a complete response (CR) or a partial response (PR). These included four patients with medulloblastoma (CR and three PRs), two with germinomas (two CRs), and one with ependymoma (one CR). The estimated 1-year survival rate was 39% (SE 12%). CONCLUSION CTX, at a maximum total dose of 6,000 mg/m2, administered sequentially with melphalan and followed by ABMR was tolerable in children with recurrent brain tumors who had not been heavily pretreated. Responses were seen in patients with medulloblastoma and germinomas. Further trials in children with chemosensitive tumors, with minimal residual disease, are planned.
17
Rosenthal, David I., Jason H. Lee, Robert Sinard, Denise A. Yardley, Mitchell Machtay, D. Marc Rosen, Merrill J. Egorin, et al. "Phase I Study of Paclitaxel Given by Seven-Week Continuous Infusion Concurrent With Radiation Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck." Journal of Clinical Oncology 19, no. 5 (March 1, 2001): 1363–73. http://dx.doi.org/10.1200/jco.2001.19.5.1363.
Full textAbstract:
PURPOSE: Paclitaxel is one of the most active agents for squamous cell carcinoma of the head and neck (SCCHN) and an in vitro radiosensitizer. The dose-response relationship for paclitaxel may depend more on exposure duration than on peak concentration. This National Cancer Institute–sponsored phase I trial was designed to determine the feasibility of combining continuous-infusion (CI) paclitaxel with concurrent radiation therapy (RT). PATIENTS AND METHODS: Patients with previously untreated stage IVA/B SCCHN were eligible. Primary end points were determination of the maximum-tolerated dose, dose-limiting toxicity, and pharmacokinetics for paclitaxel given by CI (24 hours a day, 7 days a week for 7 weeks) during RT (70 Gy/7 weeks). RESULTS: Twenty-seven patients were enrolled and assessable for toxicity. Nineteen of the patients who completed ≥ 70 Gy were assessable for response. Grade 3 skin and mucosal acute reactions occurred at 10.5 mg/m2/d, but uninterrupted treatment was possible in five of six patients. At 17 mg/m2/d, skin toxicity required a 2-week treatment break for all three patients. The mean paclitaxel serum concentration at dose levels ≥ 6.5 mg/m2/d exceeded that reported to achieve in vitro radiosensitization. Initial locoregional control was achieved in 14 (58%) of 24 of patients treated to 70 Gy, and control persisted in nine (38%). CONCLUSION: CI paclitaxel with concurrent RT is a feasible and tolerable regimen for patients with advanced SCCHN and good performance status. Preliminary response and survival data are encouraging and suggest that further study is indicated. The recommended phase II dose of paclitaxel by CI is 10.5 mg/m2/d with RT for SCCHN.
18
Ajani, Jaffer A., Paul F. Mansfield, Patrick M. Lynch, Peter W. Pisters, Barry Feig, Pamela Dumas, Douglas B. Evans, et al. "Enhanced Staging and All Chemotherapy Preoperatively in Patients with Potentially Resectable Gastric Carcinoma." Journal of Clinical Oncology 17, no. 8 (August 1999): 2403. http://dx.doi.org/10.1200/jco.1999.17.8.2403.
Full textAbstract:
PURPOSE: Patients with local-regional gastric carcinoma have a low rate of curative resection (R0) because of the advanced stage at diagnosis and suboptimal clinical staging. This study was designed to improve clinical staging with the use of laparoscopy and endoscopic ultrasonography (EUS) and to improve R0 resection rates and tolerance by delivering all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. PATIENTS AND METHODS: All patients with histologic proof of localized adenocarcinoma of the stomach underwent a staging laparoscopy before registration. EUS was performed when feasible. The intention was to administer up to five courses of preoperative chemotherapy consisting of fluorouracil (500 mg/m2/d as a continuous infusion on days 1 through 5 and as a bolus on days 12 and 19), interferon alfa-2b (3 million units subcutaneously three times a week for 3 weeks), and cisplatin (15 mg/m2/d as a bolus on days 1 through 5). After chemotherapy, surgery was attempted to remove the primary and regional lymph nodes. Clinical response and EUS staging were correlated with surgical pathology. The feasibility of this approach, resection rates, patient survival, and patterns of failure also were assessed. RESULTS: All 30 patients enrolled were assessed for toxicity, response, and survival. Nineteen men and 11 women were enrolled. The median number of courses delivered per patient was three (range, one to five courses). Fourteen patients (47%) received all five preoperative courses of chemotherapy. The overall clinical response rate was 34%. Twenty-nine patients (97%) underwent attempted resection. Twenty-five (83%) had an R0 resection. Two patients (7%) had no evidence of carcinoma in the surgical specimen, and three had only microscopic carcinoma (≥ 90% necrosis). Posttreatment EUS findings did not correlate well with surgical pathology. The median duration of follow-up was 30 months (range, 5 months to 65+ months). The median survival time for 30 patients, calculated by the Kaplan-Meier method, was 30 months (range, 5 months to 65+ months). There were no cases of grade 4 toxicity. CONCLUSION: It is feasible to administer prolonged preoperative therapy in patients with potentially resectable gastric carcinoma. Enhanced staging with laparoscopy and EUS helped in proper selection of patients and better characterization of the stage.
19
JASCHHOF, MATHIAS, and CATRIN JASCHHOF. "The Porricondylini (Diptera: Cecidomyiidae: Porricondylinae) of Sweden revisited: descriptions of nineteen new species of ten genera, including a new genus." Zootaxa 4728, no. 2 (January 22, 2020): 151–82. http://dx.doi.org/10.11646/zootaxa.4728.2.1.
Full textAbstract:
The taxonomy of the tribe Porricondylini is revisited using male adult specimens from Sweden, whose morphology was studied by transmitted-light microscope. Results communicated here include both descriptions of new taxa (one genus, 19 species) and considerably expanded species distributions (five new Fennoscandian records). New taxa, all to be attributed to both authors, are Cassidoides cornutus sp. nov., Coccopsilis pectinata sp. nov., Cocc. recondita sp. nov., Cocc. scalpta sp. nov., Dendrepidosis lapponica sp. nov., D. upplandica sp. nov., Monepidosis difficilis sp. nov., M. hybrida sp. nov., Neocolpodia ombergensis sp. nov., Oelandyla rostrata gen. et sp. nov., Parepidosis kaltisbackensis sp. nov., Paurodyla serrata sp. nov., Porricondyla bidentula sp. nov., Porr. diversicornis sp. nov., Porr. gemina sp. nov., Porr. ottenbyensis sp. nov., Porr. pallidigenae sp. nov., Spungisomyia carinaolssonae sp. nov., and S. svemapro sp. nov. Species recorded in Fennoscandia for the first time are Bryocrypta angustata Mamaev (previously known from Latvia and European Russia), B. lobata Mamaev (previously Ukraine), Isocolpodia unidentata (Marikovskij) comb. nov. (previously Kazakhstan), Monepidosis duplicis Mamaev (previously Latvia and Far East Russia), and Zaitzeviola dubitabila (Mamaev & Zaitzev) (previously Far East Russia). The morphology of males of the newly recorded species is redescribed. Monepidosis tinnerti Jaschhof & Jaschhof, 2015 syn. nov. is revealed to be a junior synonym of M. duplicis Mamaev, 1998.
20
Miller, Todd Q., and Robert J. Volk. "Family Relationships and Adolescent Cigarette Smoking: Results from a National Longitudinal Survey." Journal of Drug Issues 32, no. 3 (July 2002): 945–72. http://dx.doi.org/10.1177/002204260203200314.
Full textAbstract:
The current study used national survey data to identify which aspects of family relationships are predictive of experimental and daily cigarette smoking. A multi-wave longitudinal survey periodically assessed adolescents aged 11 to 17 (N = 1,725) over a seven year follow-up period. Parent interviewers were obtained at the initial screening. Nineteen indicators of family relationships were used based on parent and child interviews. Several indicators of smoking were used including first time cigarette smoking, a nine-point scale of intensity of experimentation with cigarettes, an indicator of daily smoking, and an indicator of smoking at least five or more cigarettes per day. Logistic and multiple regression analyses that controlled for ethnicity, gender, and socioeconomic status found that family relationships were only predictive for subjects under the age of 18. Significant predictors were (a) indices of parental attachment, (b) indices of time spent with one's family, (c) having older siblings who smoke, (d) family structure, (e) family stress, (g) parental negative labeling of the child, and (h) parental leniency towards delinquent acts. We conclude that several aspects of family relationships are important predictors of adolescent cigarette smoking and predict daily smoking more strongly than initial smoking.
21
Lightowler, Helen J., and G. Jill Davies. "Iodine intake and iodine deficiency in vegans as assessed by the duplicate-portion technique and urinary iodine excretion." British Journal of Nutrition 80, no. 6 (December 1998): 529–35. http://dx.doi.org/10.1017/s0007114598001627.
Full textAbstract:
I intake and I deficiency were investigated in thirty vegans (eleven males and nineteen females) consuming their habitual diet. I intake was estimated using the chemical analysis of 4 d weighed duplicate diet collections. The probability of I-deficiency disorders (IDD) was judged from the measurement of urinary I excretion in 24 h urine specimens during the 4 d. There was wide variation in I intake. Mean I intake in males was lower than the reference nutrient intake (RNI; Department of Health, 1991) and mean intake in females was above the RNI, although 36% males and 63% females had I intakes below the lower RNI. Mean I intake in subjects who consumed seaweed (n 3) was in excess of the RNI, and approached the provisional maximum tolerable daily intake (World Health Organization/Food and Agriculture Organization Joint Expert Committee on Food Additives, 1989). The probability of IDD in the group investigated was moderate to severe: three of five subgroups were classified as moderate and two subgroups were classified as severe IDD possibility. The findings highlight that vegans are an ‘at risk’ group for I deficiency. The I status of vegans and the subclinical effects of low I intakes and infrequent high I intakes on thyroid function in this group should be further studied. Our work has also raised the question of adequate I intakes in groups where cow's milk is not consumed, and has exposed a need for more research in this area.
22
Paniagua, Ramón, Dante Amato, Ricardo Correa–Rotter, Alfonso Ramos, Edward F. Vonesh, and Salim K. Mujais. "Correlation between Peritoneal Equilibration Test and Dialysis Adequacy and Transport Test, for Peritoneal Transport Type Characterization." Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis 20, no. 1 (January 2000): 53–59. http://dx.doi.org/10.1177/089686080002000110.
Full textAbstract:
Objective The aim of this study was to analyze the correlation between the peritoneal equilibration test (PET) and the dialysis adequacy and transport test (DATT) for peritoneal transport type characterization, and the degree of patients’ acceptance for each test. Design Cross-sectional, observational multicenter study. Setting Five referral (tertiary) dialysis centers of institutional practice. Patients The study included 107 adult continuous ambulatory peritoneal dialysis (CAPD) patients with a prescription of four exchanges of 2 L per day, irrespective of age, gender, cause of end-stage renal disease, time on dialysis, nutritional status, or residual renal function. Patients on immunosuppressive therapy and those with cancer, hepatitis B, or HIV, and those having a peritonitis episode within the previous 30 days, or three or more episodes during the previous 12 months, were excluded. Main Measures Peritoneal transport type as classified by creatinine and urea dialysis-to-plasma (D/P) ratios by PET and DATT. Results Correlation coefficients between D/P ratios for creatinine and urea, obtained for the PET and the DATT, were 0.73 for D/P creatinine and 0.96 for D/P urea. Patients were classified into high, high-average, low-average, and low transport categories according to the mean and standard deviation of D/P creatinine values obtained from the PET at 4 hours. These values showed excellent concordance with those generated from the DATT data (κ = 0.82, 95% confidence interval 0.67 – 0.93). Nineteen percent of patients showed discordance in their category when classified according to the PET versus the DATT. Patients’ acceptance was better for the DATT than for the PET, as evaluated with a questionnaire. Conclusion The DATT is an easy, inexpensive, and reliable test to assess peritoneal transport type, and it also provides information about peritoneal clearance of solutes and ultrafiltration. The DATT has better patient acceptance than the PET. Since the DATT has only been validated for patients on a fixed CAPD daily schedule of 4 x 2 L, the results should be confined only to patients receiving such a prescription.
23
Boonma, Nida, and Rosukhon Swatevacharkul. "The effect of autonomous learning process on learner autonomy of English public speaking students." Indonesian Journal of Applied Linguistics 10, no. 1 (June 1, 2020): 194–205. http://dx.doi.org/10.17509/ijal.v10i1.25037.
Full textAbstract:
Buta The objectives of this study were to examine the effect of the autonomous learning process (ALP) on learner autonomy of undergraduate students in English public speaking class and its effect size; and to explore how learner autonomy is revealed through the ALP. This study employed a variant of a mixed-methods approach, which is an embedded experimental design. Employing the cluster sampling method, nineteen Thai students were included. The students were trained in the ALP based on the four dimensions of learner autonomy (technical, psychological, political-critical, and sociocultural.) Quantitative data were collected from the Learner Autonomy for Public Speaking (LAPS) questionnaires and analyzed by the dependent samples t-test. Qualitative data were drawn from the Overall Written Reflections, and thematic content analysis was used to analyze the data. The findings revealed that the level of students’ learner autonomy in the post-questionnaire significantly increased from the pre-questionnaire (p = 0.00). Its effect size is large (d = 1.28), and learner autonomy, as revealed through the ALP, can be classified into five emerging themes. The themes are (1) use and plans of the learning strategies, (2) evaluation of learning and learning strategies, (3) capacity to provide and accept praise and criticism, (4) increased positive emotions and (5) sense of awareness and a better understanding of self. Recommendations for further study are provided.The objectives of this study were to examine the effect of the autonomous learning process (ALP) on learner autonomy of undergraduate students in English public speaking class and its effect size; and to explore how learner autonomy is revealed through the ALP. This study employed a variant of a mixed-methods approach, which is an embedded experimental design. Employing the cluster sampling method, nineteen Thai students were included. The students were trained in the ALP based on the four dimensions of learner autonomy (technical, psychological, political-critical, and sociocultural.) Quantitative data were collected from the Learner Autonomy for Public Speaking (LAPS) questionnaires and analyzed by the dependent samples t-test. Qualitative data were drawn from the Overall Written Reflections, and thematic content analysis was used to analyze the data. [A1] The findings revealed that the level of students’ learner autonomy in the post-questionnaire significantly increased from the pre-questionnaire (p = 0.00). Its effect size is large (d = 1.28), and learner autonomy, as revealed through the ALP, can be classified into five emerging themes. [A2] The themes are (1) use and plans of the learning strategies, (2) evaluation of learning and learning strategies, (3) capacity to provide and accept praise and criticism, (4) increased positive emotions and (5) sense of awareness and a better understanding of self. Recommendations for further study are provided. [A1]S-V agreement [A2]Emerging themes or emerging themes, or emergent themes?
24
Blackall, P. J., Anders Miki Bojesen, Henrik Christensen, and Magne Bisgaard. "Reclassification of [Pasteurella] trehalosi as Bibersteinia trehalosi gen. nov., comb. nov." International Journal of Systematic and Evolutionary Microbiology 57, no. 4 (April 1, 2007): 666–74. http://dx.doi.org/10.1099/ijs.0.64521-0.
Full textAbstract:
[Pasteurella] trehalosi is an important pathogen of sheep, being primarily associated with serious systemic infections in lambs but also having an association with pneumonia. The aim of the present investigation was to characterize a broad collection of strains tentatively identified as [P.] trehalosi in order to reclassify and rename this taxon to support improvements in our understanding of the pathogenesis and epidemiology of this important organism. The type strain for [P.] trehalosi, strain NCTC 10370T, was included along with 42 field isolates from sheep (21), cattle (14), goats (1), roe deer (3) and unknown sources (3). An extended phenotypic characterization was performed on all 43 strains. Amplified fragment length polymorphism (AFLP) was also performed on the isolates. Two of the field isolates were subjected to 16S rRNA gene sequencing. These sequences, along with five existing sequences for [P.] trehalosi strains and 12 sequences for other taxa in the family Pasteurellaceae, were subjected to a phylogenetic analysis. All the isolates and the reference strains were identified as [P.] trehalosi. A total of 17 out of 22 ovine isolates produced acid from all glycosides, while only four out of 14 bovine isolates produced acid from all glycosides. All 22 ovine isolates were haemolytic and CAMP-positive, while no other isolate was haemolytic and only two bovine isolates were CAMP-positive. Nineteen AFLP types were found within the [P.] trehalosi isolates. All [P.] trehalosi isolates shared at least 70 % similarity in AFLP patterns. The largest AFLP type included the type strain and 7 ovine field isolates. Phylogenetic analysis indicated that the seven strains studied (two field isolates and the five serovar reference strains) are closely related, with 98.6 % or higher 16S rRNA gene sequence similarity. As both genotypic and phenotypic testing support the separate and distinct nature of these organisms, we propose the transfer of [P.] trehalosi to a new genus, Bibersteinia, as Bibersteinia trehalosi comb. nov. The type strain is NCTC 10370T (=ATCC 29703T). Bibersteinia trehalosi can be distinguished from the existing genera of the family by the observation of only nine characteristics; catalase, porphyrin, urease, indole, phosphatase, acid from dulcitol, (+)-d-galactose, (+)-d-mannose and (+)-d-trehalose.
25
López-Argumedo, G., G. López-Vivanco, R. Fernández, I. Díaz de Corcuera, A. Sancho, I. Rubio, A. Martínez-Bueno, J. Mañé, A. Muñoz, and R. Barceló. "Concurrent chemoradiotherapy (crt) with weekly docetaxel (d) for advanced head and neck cancer." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 15516. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.15516.
Full textAbstract:
15516 Background: Concomitant CRT has become a standard treatment for advanced head and neck cancer. The aim of this study was to evaluate the efficacy and toxicity of concurrent CRT with D in patients (pts) with advanced squamous cell carcinoma of head and neck (SCCHN). Methods: Patients with untreated and unresectable stage III or IV (M0) squamous cell carcinoma of head and neck were included. Treatment consisted of D 20 mg/m2 weekly with concomitant radiotherapy 70 Gy (2 Gy per day, 7 weeks). Results: From September 03 to October 05, sixty-four pts with advanced SCCHN, were recruited. Gender: 61 male, 3 female. Mean age: 56.5 years old (range 42–77). ECOG PS 0/1/2: 0/57/7. Primary sites of disease: oral cavity 8, oropharynx 26, hypopharynx 15 and larynx 15. Stage III 16 pts and stage IV 48 pts. Compliance: 393 administrations of D were given, median 6, mean 6 (range 1–8). Fifty-five pts (86%) completed the radiotherapy dose planned (mean dose of RT was 66 Gy). One refused more treatment with D after first administration. Nineteen pts required supportive percutaneous gastrostomy or nasogastric tubes previously or during therapy. Grade 2/3/4 toxicity per patient: anemia 4/2/0, mucositis 21/24/0, dermatitis 21/20/0. Neither thrombopenia nor neutropenia were observed. Four pts died of aspiration pneumonia during treatment, one of gastric perforation and two of unknown causes. Fifty-six pts were evaluable for response: CR 28 (44%), PR 23 (36%), SD 2 (3%), PD 3 (5%), with an overall response rate of 80%. Median overall survival was 74.86 weeks (95% CI: 40.40–109.32) and median progression free survival was 48 weeks (95% CI: 18.80–77.20). With a median follow up of 40 weeks 34 pts (53%) were alive and 21 of them (33%) remained free of disease. Conclusions: Concurrent weekly D with conventional radiotherapy showed a high response rate. Toxicity was manageable and allowed maintaining radiotherapy administration. Taking into account poor prognostic factors of our series, survival results seem promising. No significant financial relationships to disclose.
26
CRISTINO, MARIA DA GLÓRIA G., CARLA CAROLINA F. DE MENESES, MALÚCIA MARQUES SOEIRO, JOÃO ELIAS V. FERREIRA, ANTONIO FLORÊNCIO DE FIGUEIREDO, JARDEL PINTO BARBOSA, RUTH C. O. DE ALMEIDA, JOSÉ C. PINHEIRO, and ANDRÉIA DE LOURDES R. PINHEIRO. "COMPUTATIONAL MODELING OF ANTIMALARIAL 10-SUBSTITUTED DEOXOARTEMISININS." Journal of Theoretical and Computational Chemistry 11, no. 02 (April 2012): 241–63. http://dx.doi.org/10.1142/s0219633612500162.
Full textAbstract:
Nineteen 10-substitued deoxoartemisinin derivatives and artemisinin with activity against D-6 strains of malarial falciparum designated as Sierra Leone are studied. We use molecular electrostatic potential maps in an attempt to identify key structural features of the artemisinins that are necessary for their activities and molecular docking to investigate the interaction with the molecular receptor (heme). Chemometric modeling: Principal Component Analysis (PCA), Hierarchical Cluster Analysis (HCA), K-Nearest Neighbor (KNN), Soft Independent Modeling of Class Analogy (SIMCA) and Stepwise Discriminant Analysis (SDA) are employed to reduce dimensionality and investigate which subset of descriptors are responsible for the classification between more active (MA) and less active (LA) artemisinins. The PCA, HCA, KNN, SIMCA and SDA studies showed that the descriptors LUMO (Lowest Unoccupied Molecular Orbital) energy, DFeO1 (Distance between the O 1 atom from ligand and iron atom from heme), X1A (Average Connectivity Index Chi-1) and Mor15u (Molecular Representation of Structure Based on Electron Diffraction) code of signal 15, unweighted, are responsible for separating the artemisinins according to their degree of antimalarial activity. The prediction study was done with a new set of eight artemisinins by using the chemometric methods and five of them were predicted as active against D-6 strains of falciparum malaria. In order to verify if the key structural features that are necessary for their antimalarial activities were investigated for the interaction with the heme, we also carried out calculations of the molecular electrostatic potential (MEP) and molecular docking. MEP maps and molecular docking were analyzed for more active compounds of the prediction set.
27
Wu, Ze Rui, Yong Zhang, Lin Cai, Shao Jian Lin, Zhi Peng Su, Yong Xu Wei, Han Bing Shang, Wen Lei Yang, Wei Guo Zhao, and Zhe Bao Wu. "Long-Term Clinical Outcomes of Invasive Giant Prolactinomas after a Mean Ten-Year Followup." International Journal of Endocrinology 2016 (2016): 1–7. http://dx.doi.org/10.1155/2016/8580750.
Full textAbstract:
Objective. The aim of this study is to observe clinical outcomes after more than ten years of followup in a group of patients with invasive giant prolactinomas (IGPs) treated with dopamine agonists (DAs).Methods. Twenty-five patients met the criteria of IGPs, among which 16 patients primarily received bromocriptine (BRC) and the other nine had undergone unsuccessful microsurgery prior to BRC treatment.Results. After a mean follow-up period of135.5±4.7months, the clinical symptoms in all patients improved by different degrees. Tumor volume was decreased by a mean of 98.6%, and the tumors of 19 patients had almost completely disappeared. The mean duration of treatment at maximal doses of BRC was 48.5 months. At the last follow-up visit, nineteen patients had normal PRL levels, and 14 of these patients had received the low-dose BRC treatment (at an average of2.9±0.3 mg/d). Younger patients < 25 years had a significantly higher rate of persistent hyperprolactinemia after long-term BRC treatment (p=0.043).Conclusion. DAs are a first-line therapy for IGPs because they can effectively achieve long-term control in both shrinking tumor volume and normalizing the PRL level, and majority of patients need low-dose DA maintenance. Younger patients are prone to persistent hyperprolactinemia despite long-term DA treatment.
28
Dann, E. J., J. Anastasi, and R. A. Larson. "High-dose cladribine therapy for chronic myelogenous leukemia in the accelerated or blast phase." Journal of Clinical Oncology 16, no. 4 (April 1998): 1498–504. http://dx.doi.org/10.1200/jco.1998.16.4.1498.
Full textAbstract:
PURPOSE A phase II clinical trial was performed to evaluate the effectiveness of high-dose cladribine (2CDA) for treatment of chronic myelogenous leukemia (CML) in the accelerated or blast phase. PATIENTS AND METHODS Nineteen patients were treated. The median age was 55 years (range, 30 to 73). Six were older than 60 years. Eight had progressed after intensive combination chemotherapy and three after allogeneic or autologous transplantation. For the first course, 16 patients received 2CDA at 15 mg/m2/d intravenously (i.v.) over 1 hour for 5 days. Two received 18 mg/m2 and one received 21.5 mg/m2 daily. The second course was escalated to 20 mg/m2/d in five patients. RESULTS Rapid cytoreduction of leukemia occurred in the blood, with the nadir at 10 to 12 days. The median WBC count decreased from 36,900/microL before treatment to 500/microL at the nadir and recovered to 5,200/microL at day 30. The median platelet count changed from 113,000/microL to 24,000/microL at the nadir and 71,000/microL at day 30. The complete remission (CR) plus partial remission (PR) rate was 47% (95% confidence interval [CI], 23% to 72%). One 64-year-old man with lymphoid blast phase of CML had a morphologic and cytogenetic CR that lasted 9 months. The median survival for all patients was 34 weeks, and the median survival for the eight responders was 56 weeks (range, 11 to 167). The median number of days spent in hospital over the entire treatment period was 19 (range, 4 to 60). CONCLUSION High-dose 2CDA therapy provides effective palliation for CML in accelerated or blast phases, even for heavily pretreated patients.
29
Devkota, P., HK Manandhar, and PB Khadka. "Spinal Injuries in a Tertiary Care Referral Center of Western Nepal." Nepal Journal of Medical Sciences 2, no. 2 (October 23, 2013): 156–59. http://dx.doi.org/10.3126/njms.v2i2.8967.
Full textAbstract:
Background: Spinal injury is a devastating condition often affecting young and healthy individuals around the world. This devastating injury not only creates enormous physical and emotional cost to individuals but also gives tremendous financial burden to the society. We evaluate the demography, types and causes of the spinal injuries and their management in patients admitted in a hospital. Methods: Medical records of 45 patients who were presented with spinal injuries in a year were analyzed. The age, sex, mode of injury, sites, types and level of injury, hospital stay, and treatment given were analyzed. Frankel grading was used for the evaluation of the neurological deficits. Results: The mean age of the patient was 47.5 years (range 19 - 78). Male patients were 60% (n=27) and female 40% (n=18). There were 42.2% (n=19) patients with E grade, 24.4% (n=11) patients with C grade, 20% (n=9) patients with D, three 6.6% (n=3) patients with A and B grades each of patients according to Frankel grade. Lumbar spine was the commonest site of injury. The most common cause of injury was fall, followed by road traffic accidents (RTA) and others. Nineteen patients were treated conservatively, 16 were operated, five patients were referred to other centers due to various reasons and the other five patients were discharged on their request. Conclusions: Spinal injuries are one of the rapidly growing injuries in our society and the commonest mode of injury was fall. The majority of patients were from the hilly areas. Nepal Journal of Medical Sciences | Volume 02 | Number 02 | July-December 2013 | Page 156-159 DOI: http://dx.doi.org/10.3126/njms.v2i2.8967
30
Shah, Gaurav D., Joachim Yahalom, Denise D. Correa, Rose K. Lai, Jeffrey J. Raizer, David Schiff, Renato LaRocca, Barbara Grant, Lisa M. DeAngelis, and Lauren E. Abrey. "Combined Immunochemotherapy With Reduced Whole-Brain Radiotherapy for Newly Diagnosed Primary CNS Lymphoma." Journal of Clinical Oncology 25, no. 30 (October 20, 2007): 4730–35. http://dx.doi.org/10.1200/jco.2007.12.5062.
Full textAbstract:
Purpose Our goals were to evaluate the safety of adding rituximab to methotrexate (MTX)-based chemotherapy for primary CNS lymphoma, determine whether additional cycles of induction chemotherapy improve the complete response (CR) rate, and examine effectiveness and toxicity of reduced-dose whole-brain radiotherapy (WBRT) after CR. Patients and Methods Thirty patients (17 women; median age, 57 years; median Karnofsky performance score, 70) were treated with five to seven cycles of induction chemotherapy (rituximab, MTX, procarbazine, and vincristine [R-MPV]) as follows: day 1, rituximab 500 mg/m2; day 2, MTX 3.5 gm/m2 and vincristine 1.4 mg/m2. Procarbazine 100 mg/m2/d was administered for 7 days with odd-numbered cycles. Patients achieving CR received dose-reduced WBRT (23.4 Gy), and all others received standard WBRT (45 Gy). Two cycles of high-dose cytarabine were administered after WBRT. CSF levels of rituximab were assessed in selected patients, and prospective neurocognitive evaluations were performed. Results With a median follow-up of 37 months, 2-year overall and progression-free survival was 67% and 57%, respectively. Forty-four percent of patients achieved a CR after five or fewer cycles, and 78% after seven cycles. The overall response rate was 93%. Nineteen of 21 CR patients received the planned 23.4 Gy WBRT. The most commonly observed grade 3 to 4 toxicities included neutropenia (43%), thrombocytopenia (36%), and leukopenia (23%). No treatment-related neurotoxicity has been observed. Conclusion The addition of rituximab to MPV increased the risk of significant neutropenia requiring routine growth factor support. Additional cycles of R-MPV nearly doubled the CR rate. Reduced-dose WBRT was not associated with neurocognitive decline, and disease control to date is excellent.
31
Iglebekk, Wenche, Carsten Tjell, and Peter Borenstein. "Pain and other symptoms in patients with chronic benign paroxysmal positional vertigo (BPPV)." Scandinavian Journal of Pain 4, no. 4 (October 1, 2013): 233–40. http://dx.doi.org/10.1016/j.sjpain.2013.06.004.
Full textAbstract:
AbstractBackground and aimA diagnosis of chronic benign paroxysmal positional vertigo (BPPV) is based on brief attacks of rotatory vertigo and concomitant nystagmus elicited by rapid changes in head position relative to gravity. However, the clinical course of BPPV may vary considerably from a self-limiting to a persisting and/or recurrent disabling problem. The authors’ experience is that the most common complaints of patients with chronic BPPV are nautical vertigo or dizziness with other symptoms including neck pain, headache, widespread musculoskeletal pain, fatigue, and visual disturbances. Trauma is believed to be the major cause of BPPV in individuals younger than fifty years. Chronic BPPV is associated with high morbidity. Since these patients often suffer from pain and do not have rotatory vertigo, their symptoms are often attributed to other conditions. The aim of this study was to investigate possible associations between these symptoms and chronic BPPV.MethodsDuring 2010 a consecutive prospective cohort observational study was performed. Diagnostic criteria: (A) BPPV diagnosis confirmed by the following: (1) a specific history of vertigo/dizziness evoked by acceleration/deceleration, (2) nystagmus in the first position of otolith repositioning maneuvers, and (3) appearing and disappearing nystagmus during the repositioning maneuvers; (B) the disorder has persisted for at least six months. (C) Normal MRI of the cerebrum. Exclusion criteria: (A) Any disorder of the central nervous system (CNS), (B) migraine, (C) active Ménière’s disease, and (D) severe eye disorders. Symptom questionnaire (‘yes or no’ answers during a personal interview) and Dizziness Handicap Inventory (DHI) were used.ResultsWe included 69 patients (20 males and 49 females) with a median age of 45 years (range 21-68 years). The median duration of the disease was five years and three months. The video-oculography confirmed BPPV in more than one semicircular canal in all patients. In 15% there was a latency of more than 1 min before nystagmus occurred. The Dizziness Handicap Inventory (DHI) median score was 55.5 (score >60 indicates a risk of fall). Seventy-five percent were on 50-100% sick leave. Eighty-one percent had a history of head or neck trauma. Nineteen percent could not recall any history of trauma. In our cohort, nautical vertigo and dizziness (81%) was far more common than rotatory vertigo (20%). The majority of patients (87%) reported pain as a major symptom: neck pain (87%), headache (75%) and widespread pain (40%). Fatigue (85%), visual disturbances (84%), and decreased concentration ability (81%) were the most frequently reported symptoms. In addition, unexpected findings such as involuntary movements of the extremities, face, neck or torso were found during otolith repositioning maneuvers (12%). We describe one case, as an example, how treatment of his BPPV also resolved his chronic, severe pain condition.ConclusionThis observational study demonstrates a likely connection between chronic BPPV and the following symptoms: nautical vertigo/dizziness, neck pain, headache, widespread pain, fatigue, visual disturbances, cognitive dysfunctions, nausea, and tinnitus.ImplicationsPatients with complex pain conditions associated with nautical vertigo and dizziness should be evaluated with the Dizziness Handicap Inventory (DHI)-questionnaire which can identify treatable balance disorders in patients with chronic musculoskeletal pain.
32
Gruhn, Bernd, Nadine Pfaffendorf, Susan Wittig, Roland Zell, Ralf Häfer, Daniel Steinbach, Falko H. Herrmann, and Felix Zintl. "Presence of Preleukemic Clones at Birth in the Majority of Children with B-Lineage Acute Lymphoblastic Leukemia." Blood 106, no. 11 (November 16, 2005): 88. http://dx.doi.org/10.1182/blood.v106.11.88.88.
Full textAbstract:
Abstract The proof for the prenatal origin of childhood acute lymphoblastic leukemia (ALL) comes from the detection of concordant leukemia in monozygotic twins and the identification of translocation breakpoint genomic sequences at birth in a limited number of ALL patients with t(4;11) or t(12;21) chromosomal translocation. However, most patients with childhood ALL lack leukemia-specific fusion gene sequences. Therefore, we have used the rearranged immunoglobulin heavy chain (IgH) genes as a marker for the detection of preleukemic clones at birth. Guthrie card blood spots of 32 children with B-lineage ALL treated at our institution were available for this retrospective study. The ALL patients had a median age of 5 years (range, 15 months to 14 years) and had median presenting white blood cell (WBC) counts of 10150/μl (range, 800 to 103800/μl). In all patients a monoclonal IgH gene rearrangement was obtained from diagnostic bone marrow and sequenced. Clone-specific primers were designed using the specific D-N-J and N-D-N sequences. A two-stage polymerase chain reaction (PCR) using a semi-nested approach was developed to improve sensitivity and specificity of amplification. In all 32 patients, one leukemic cell could be detected in a background of 105 normal blood mononuclear cells. Nineteen of the 32 patients (59%) had detectable IgH gene rearrangements at birth using the sensitive semi-nested PCR. Sequencing of the PCR products obtained from Guthrie card blood spots revealed the identical sequences identified from diagnostic leukemic cells. The fetal characteristics of the leukemic cells were indicated by the small numbers of nucleotides inserted into the N region and the shortened D germ line segments. Interestingly, five of the six children (83%) with hyperdiploid ALL had detectable preleukemic clones at birth. Four of the five children (80%) with pro-B ALL, 13 of the 21 children (62%) with cALL and only two of the six children (33%) with pre-B ALL had preleukemic clones on their cards. We did not observe any differences in age at diagnosis or presenting WBC count between the 19 patients with preleukemic clones at birth and the 13 patients whose Guthrie cards were tested negative. Our results suggest that the majority of children with B-lineage ALL has preleukemic clones already at birth indicating a prenatal origin of leukemia. In addition, postnatal factors are important in leukemogenesis as well because of the long latency periods until clinical diagnosis of leukemia.
33
Booth-McLean, M. E., K. S. Schwartzkopf-Genswein, F. A. Brown, C. L. Holmes, A. L. Schaefer, T. A. McAllister, and G. J. Mears. "Physiological and behavioural responses to short-haul transport by stock trailer in finished steers." Canadian Journal of Animal Science 87, no. 3 (September 1, 2007): 291–97. http://dx.doi.org/10.4141/a06-033.
Full textAbstract:
Nineteen British cross-bred steers (623 ± 10.6 kg) were transported in groups of four or five for 3 h and returned to their home pens. Jugular cannulas, heart rate (HR; BPM) monitors and radio transmitters were used to non-invasively collect physiological data. Heart rate (n = 13) was lower during highway travel (83.5 ± 3.15, P > 0.05) compared with pre-loading (118.9 ± 3.19, P < 0.01) and off-loading (97.5 ± 4.47) but was not different from travel in town (88.8 ± 2.90). Plasma cortisol concentration (µg dL-1, n = 16) increased from pre-loading (1.87 ± 0.28) to off-loading (3.10 ± 0.28, P < 0.02) and decreased to 1.16 ± 0.28 µg dL-1 by 1 h after off-loading (P < 0.001), a value not different from pre-loading levels. Body temperature measured at offloading was 0.19°C higher (P < 0.001) than at pre-loading. No differences in the time spent eating and ruminating were observed when compared between a 1-h period 1 d prior to transport and the same time of day post-transport (P > 0.50). Increases in HR (P < 0.01) and lying time (P < 0.001) post-transport compared with the days prior suggest cattle experienced some fatigue. Mild, short-term stress responses were observed in finished steers exposed to 3 h of transportation. Key words: Cortisol, heart rate, hematocrit, behaviour, steers, transportation
34
Mollard, R. C., B. L. Luhovyy, S. Panahi, M. Nunez, A. Hanley, and G. H. Anderson. "Regular consumption of pulses for 8 weeks reduces metabolic syndrome risk factors in overweight and obese adults." British Journal of Nutrition 108, S1 (August 23, 2012): S111—S122. http://dx.doi.org/10.1017/s0007114512000712.
Full textAbstract:
Pulses are low in energy density, supporting their inclusion in the diet for the management of risk factors of the metabolic syndrome (MetSyn). The aim of the present study was to describe the effects of frequent consumption (five cups/week over 8 weeks) of pulses (yellow peas, chickpeas, navy beans and lentils), compared with counselling to reduce energy intake by 2093 kJ/d (500 kcal/d), on risk factors of the MetSyn in two groups (nineteen and twenty-one subjects, respectively) of overweight or obese (mean BMI 32·8 kg/m2) adults. Body weight, waist circumference, blood pressure, fasting blood parameters and 24 h food intakes were measured at weeks 1, 4 and 8. Blood glucose, insulin, C-peptide, glucagon-like peptide-1 (GLP-1) and ghrelin were measured after a 75 g oral glucose load at weeks 1 and 8. At week 8, both groups reported reductions in energy intake, waist circumference, systolic blood pressure, glycosylated Hb (HbA1c) and glucose AUC and homeostasis model of insulin resistance (HOMA-IR) following the glucose load (P < 0·05). However, HDL, fasting C-peptide and insulin AUC responses were dependent on diet (P < 0·05). HDL and C-peptide increased by 4·5 and 12·3 %, respectively, in the pulse group, but decreased by 0·8 and 7·6 %, respectively, in the energy-restricted group. Insulin AUC decreased in both females and males on the energy-restricted diet by 24·2 and 4·8 %, respectively, but on the pulse diet it decreased by 13·9 % in females and increased by 27·3 % in males (P < 0·05). In conclusion, frequent consumption of pulses in an ad libitum diet reduced risk factors of the MetSyn and these effects were equivalent, and in some instances stronger, than counselling for dietary energy reduction.
35
Dahl, Lisbeth, Jill A. Opsahl, Helle M. Meltzer, and Kåre Julshamn. "Iodine concentration in Norwegian milk and dairy products." British Journal of Nutrition 90, no. 3 (September 2003): 679–85. http://dx.doi.org/10.1079/bjn2003921.
Full textAbstract:
The present study was conducted to determine the iodine concentration in Norwegian-produced milk and a selection of dairy products. The iodine concentration of eighty-five samples of milk and dairy products was analysed by inductively coupled plasma–MS. Low-fat milk and organic milk were sampled from nineteen and seven different locations in Norway, respectively, during the summer and winter season of 2000. Other milk and dairy products were chiefly collected during the summer season. Low-fat milk from the summer season had significantly lower median iodine concentration (88 μg/l, range 63–122 μg/l) compared with low-fat milk from the winter season (232 μg/l, range 103–272 μg/l). The median iodine concentration of organic summer milk (60 μg/l) was significantly lower than the iodine concentration of organic winter milk (127 μg/l). There were no significant differences in the low-fat-milk samples with regard to geographical sampling location. Whey cheese (Tine Gudbrandsdalsost) iodine concentration was significantly higher (803 μg/kg) than the median iodine concentration in casein cheeses such as Jarlsberg and Norvegia of 201 and 414 μg/kg, respectively. With a recommended iodine intake of 150 μg/d for adults, a daily intake of 0.4 litres milk meets the requirement with 25% during the summer and more than 60% during the winter season. Thus, milk and dairy products are important determinants of iodine intake in Norway.
36
Furman, W. L., S. D. Baker, C. B. Pratt, G. K. Rivera, W. E. Evans, and C. F. Stewart. "Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia." Journal of Clinical Oncology 14, no. 5 (May 1996): 1504–11. http://dx.doi.org/10.1200/jco.1996.14.5.1504.
Full textAbstract:
PURPOSE To determine the maximum-tolerated systemic exposure (MTSE) and exposure-limiting toxicity of continuous infusion topotecan in children with recurrent acute leukemia. PATIENTS AND METHODS Patients received escalating levels of topotecan systemic exposure as measured by steady-state topotecan lactone concentration (Css). Samples obtained within the first 24 hours were measured by high-pressure liquid chromatography (HPLC) for topotecan. A two-compartment model was fit to the data using a Bayesian algorithm. Css was calculated for each patient; if it differed by more than 20% of target, a new dosage was begun within 6 hours. Follow-up concentrations were obtained as well as serial plasma samples postinfusion. Toxicity and evidence of activity were assessed after each course. RESULTS Thirteen boys and five girls received 23 courses of topotecan. Target Css ranged from 1.0 to 5.3 ng/mL (topotecan doses, 0.5 to 3.3 mg/m2/d). Nineteen of 23 courses were within +/- 20% of target after adjustment (range, 77% to 139%). The MTSE was 4.0 ng/mL, and mucositis was exposure-limiting at 5.3 ng/mL. A significant relation between topotecan lactone Css and the severity of mucositis was observed. Myelosuppression was experienced but was not considered exposure-limiting. One complete response and one partial response were noted. CONCLUSION The MTSE for continuous infusion topotecan was 4.0 ng/mL. Responses were noted at Css comparable to those producing responses in a severe combined immunodeficiency (SCID) mouse model. Further studies of topotecan are warranted.
37
Fruchart, Christophe, Josette Briere, Renaud Ciappuccini, Olivier Casasnovas, Herve Tilly, Franck Morschhauser, Catherine Sebban, et al. "Upfront Consolidation Combining Yttrium-90 Ibritumomab Tiuxetan and High Dose Therapy with Stem-Cell Transplantation in Poor Risk Patients with Diffuse Large B-Cell Lymphoma." Blood 120, no. 21 (November 16, 2012): 812. http://dx.doi.org/10.1182/blood.v120.21.812.812.
Full textAbstract:
Abstract Abstract 812 Background: High dose chemotherapy (HDT) with autologous stem cell transplantation (ASCT) is considered as a relevant option for upfront consolidation in patients with poor risk aggressive lymphomas (Fitoussi, hematologica 2011; 96(8):1136-1143). Adding Y90-Ibritumomab Tiuxetan to BEAM regimen would improve outcomes in relapse or refractory lymphomas. We evaluated the safety and efficacy of standard-dose Y90-Ibritumomab Tiuxetan combined with high-dose BEAM after first line induction treatment in patients under 65 years of age with poor prognosis diffuse large B-cell lymphoma (DLBCL). (clinicaltrials.gov: NCT00689169). Methods and Patients: Pathologically proven CD20+ DLBCL patients, 18–65 years of age, with IPI ≥ 2, in CR, CRu or PR according to the IWG 1999 criteria after rituximab-containing induction therapy were included. Patients received Rituximab 250 mg/m2 on d-21, Rituximab 250 mg/m2 followed by Y90-Ibritumomab Tiuxetan 0.4mCi/kg on d-14, BEAM started on d-7 followed by ASCT. FDG-PET scans evaluated using Juweid criteria were performed before transplant in all patients, but were not decisional. Patients were analyzed by immunochemistry for CD10, BCL6, MUM1 and BCL2 expression. End of treatment assessment was done at day 100 (D100). The primary end point was event-free survival (EFS) at 2 years. Results: Seventy five consecutive patients were enrolled from August 2007 to December 2008. Median age was 49 years (19–64) with 7 pts (9%) older than 60 years. The IPI score was 2 in 28 pts (37%) and >2 in 47 pts (63%), bulky disease ≥ 10 cm in 29 pts (39%) and mediastinal involvement in 20 pts (26%). Thirty six patients received 4 (14 pts) or 6 (22 pts) cycles of R-CHOP and 39 had 4 cycles of R-ACVBP as induction treatment. After induction, 63 patients (84%) were in CR or CRu and 12 (16%) were in PR, 21 pts (28%) presented with positive PET. Four pts progressed before they completed the treatment including 2 with positive PET. Median follow-up was 34 months for the 71 patients eligible for analysis. Median time to reach a neutrophil count > 500/μL and platelet count > 20 000/μL was 11 days. Neutropenic fever (100%) and mucositis (78%) occurred in most patients. Other adverse events (AE) were usually mild to moderate in severity. Twenty three AE were reported as serious, mostly infection (n=9). One of them was fatal due to septic shock. The 2-yr EFS and overall survival (OS) was 79% (95% CI: 67–88%) and 83% (95% CI: 70–88%) respectively. Fourteen pts relapsed including 9 before D100. The Overall Response Rate (CR+CRu+PR) was 83%, 59 patients (81%) achieved a CR/CRu, 2 pts were in PR. The 2-year DFS was 91% (95% CI: 80% – 96%). There were no differences in OS (p=0.9) and EFS (p=0.8) between patients in CR/Cru or in PR. Positive PET imaging before transplant did not predict treatment failure. Nineteen pts with positive PET after induction were consolidated with Y90-Ibritumomab Tiuxetan and BEAM, one died of sepsis, 18 achieved a CR/CRu and 3 relapsed at 9, 14 and 20 month. Mediastinal involvement, non-GCB phenotype and high BCL2 expression did not affect outcome. IPI score (2 v >2) and bulky disease at diagnosis appeared to be prognosis factors for OS: 96% v 75% (p = 0.02) and 91% v 70% (p=0.02) respectively, but not for EFS: 2 years EFS 89% v 73% (p = 0.09) and 84% v 70% (p=0.1) respectively. Conclusions: Adding Y90 Ibritumomab Tiuxetan to BEAM is safe without an increase in transplant-related toxicity. First line consolidation with Y90 Ibritumomab Tiuxetan and HDT induced high rates of EFS and OS in poor prognosis patients with DLBCL irrespectively of PET status after induction treatment and warrants randomized study. Disclosures: Gisselbrecht: roche: Consultancy, Research Funding; baxter: Research Funding.
38
Moulin, D. E., D. Palma, C. Watling, and V. Schulz. "Methadone in the Management of Intractable Neuropathic Noncancer Pain." Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 32, no. 3 (August 2005): 340–43. http://dx.doi.org/10.1017/s0317167100004236.
Full textAbstract:
ABSTRACT:Objective:To evaluate the role of methadone in the management of intractable neuropathic noncancer pain.Methods:A case series of 50 consecutive noncancer pain patients who were seen at a tertiary care centre and treated with oral methadone for a variety of intractable neuropathic pain states.Results:The mean age was 52.7 years and the mean duration of follow-up was 13.9 months. Post-discectomy nerve root fibrosis, complex regional pain syndrome, peripheral neuropathy and central spinal cord pain syndromes were the most common diagnoses. Over 90% had been treated with one or more tricyclic antidepressants and anticonvulsants and a similar number had received other adjuvant analgesics. All patients had failed treatment with one or more conventional opioid analgesics (mean 2.8) at a mean maximal morphine dose of 384 mg (or equivalents) per day. Twelve patients had failed spinal cord stimulation. Nineteen patients (38%) did not tolerate initial methadone titration or thought their pain was worse on methadone. Five patients (10%) declared initial benefit but required repetitive dose escalation and eventually became non-responders. Twenty-six patients (52%) reported mild (4), moderate (15), marked (6) or complete (1) pain relief and continued on methadone at a mean maintenance dose of 159.8 mg/day for a mean duration of 21.3 months. Fourteen patients (28%) reported improved function on methadone relative to previous treatments.Conclusions:Methadone appears to have unique properties including N-methyl-D-aspartate antagonist activity that may make it especially useful in the management of intractable neuropathic pain. This observation needs to be tested in randomized, controlled trials.
39
Hernández Hernández, Julio C., Cuauhtémoc Chávez, and Rurik List. "Diversidad y patrones de actividad de mamíferos medianos y grandes en la Reserva de la Biosfera La Encrucijada, Chiapas, México." Revista de Biología Tropical 66, no. 2 (May 24, 2018): 634. http://dx.doi.org/10.15517/rbt.v66i2.33395.
Full textAbstract:
Diversity and activity patterns of medium and large mammals in La Encrucijada Biosphere Reserve, Chiapas, Mexico. In Mexico, wetlands occupy an important portion of the country, among them, mangroves are particularly diverse. La Encrucijada Biosphere Reserve (ENBIRE) is a coastal ecosystem of mangrove located along the Pacific Coastal Plain in the Southwestern portion of Chiapas state. The ENBIRE mangroves are among the most important of the American Pacific Coast, highlighting the role they play in the maintenance of the community of mammals on the coast of the state. There are few studies in Mexico related to the mammals associated with these ecosystems, our aim was to estimate the diversity and activity patterns of medium and large mammals in the ENBIRE. Sampling was conducted from August 2015 to August 2016 using camera traps. We obteined 1 851 independent photographs records, with a total sampling effort of 5 400 trap-days. Nineteen species of mammals were registered belonging to 15 families and seven orders, and five species were new records to the area. Six species present are listed, two as endangered and four as threatened. Interpolation and extrapolation analyzes showed an asymptotic trend in the curves for the rainy and dry seasons. The coverage of the sample for both seasons was 99.9 % and 99.8 %, respectively, indicating that both cases were a representative sample. According to the relative abundance index obtained, the most abundant species were Procyon lotor (IAR = 4.35), Nasua narica (IAR = 3.91), Philander opossum (IAR = 2.04), Cuniculus paca (IAR = 1.89), Didelphis marsupialis (IAR = 1.67) and Dasypus novemcinctus (IAR = 1.02). In terms of patterns of activity C. paca, P. opossum, D. marsupialis and D. novemcinctus were primarily nocturnal; P. lotor showed a tendency towards nocturnal habits but was also recorded during the day; N. narica was mainly diurnal. This information can be useful to the creation of management programs and the conservation of medium and large mammals in the ENBIRE, especially for species at risk. Rev. Biol. Trop. 66(2): 634-646. Epub 2018 June 01.
40
Stodden, David F., Glenn S. Fleisig, Scott P. McLean, Stephen L. Lyman, and James R. Andrews. "Relationship of Pelvis and Upper Torso Kinematics to Pitched Baseball Velocity." Journal of Applied Biomechanics 17, no. 2 (May 2001): 164–72. http://dx.doi.org/10.1123/jab.17.2.164.
Full textAbstract:
Generating consistent maximum ball velocity is an important factor for a baseball pitcher’s success. While previous investigations have focused on the role of the upper and lower extremities, little attention has been given to the trunk. In this study it was hypothesized that variations in pelvis and upper torso kinematics within individual pitchers would be significantly associated with variations in pitched ball velocity. Nineteen elite baseball pitchers were analyzed using 3-D high-speed motion analysis. For inclusion in this study, each pitcher demonstrated a variation in ball velocity of at least 1.8 m/s (range: 1.8–3.5 m/s) during his 10 fastball pitch trials. A mixed-model analysis was used to determine the relationship between 12 pelvis and upper torso kinematic variables and pitched ball velocity. Results indicated that five variables were associated with variations in ball velocity within individual pitchers: pelvis orientation at maximum external rotation of the throwing shoulder (p= .026), pelvis orientation at ball release (p= .044), upper torso orientation at maximum external rotation of the throwing shoulder (p= .007), average pelvis velocity during arm cocking (p= .024), and average upper torso velocity during arm acceleration (p= .035). As ball velocity increased, pitchers showed an increase in pelvis orientation and upper torso orientation at the instant of maximal external rotation of the throwing shoulder. In addition, average pelvis velocity during arm cocking and average upper torso velocity during arm acceleration increased as ball velocity increased. From a practical perspective, the athlete should be coached to strive for proper trunk rotation during arm cocking as well as strength and flexibility in order to generate angular velocity within the trunk for maximum ball velocity.
41
Creemers, G. J., G. Bolis, M. Gore, G. Scarfone, A. J. Lacave, J. P. Guastalla, R. Despax, et al. "Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study." Journal of Clinical Oncology 14, no. 12 (December 1996): 3056–61. http://dx.doi.org/10.1200/jco.1996.14.12.3056.
Full textAbstract:
PURPOSE Topotecan is a topoisomerase I inhibitor with preclinical activity against various tumor types. We conducted a large multicenter phase II study with topotecan in ovarian cancer in patients who had failed to respond to one prior cisplatin-based chemotherapeutic regimen. PATIENTS AND METHODS Topotecan 1.5 mg/m2/d was administered intravenously by 30-minute infusion for 5 days repeated every 3 weeks. As the cisplatin-free interval relates to response in subsequent treatment, patients were stratified in subgroups, ie, cisplatin-refractory, cisplatin-resistant, and cisplatin-sensitive. RESULTS One-hundred eleven patients entered the study. Nineteen patients were considered to be ineligible; 92 patients were assessable for response. A total of 552 courses were given (median, four per patient; range, one to 17). The major toxicities were leukocytopenia and neutropenia, which were grade 3 to 4 in 54.2% and 69.1% of courses, respectively, but with only 4.3% of these being grade 4 neutropenia plus fever or infectious complications. Prophylactic granulocyte colony-stimulating factor (G-CSF) was given in 20.5% of courses to maintain dose-intensity. Other relatively frequent side effects were alopecia (82%), nausea (36.4%), and vomiting (17.5%). The overall response rate was 16.3%, with one complete response (CR) and 14 partial responses (PRs). In the cisplatin-refractory, cisplatin-resistant, and cisplatin-sensitive strata, the response rates were 5.9%, 17.8%, and 26.7%, respectively. The median duration of time of documented response was 21.7 weeks (range, 4.6 to 41.9). CONCLUSION Topotecan in a daily-times-five schedule is an effective regimen as second-line treatment in ovarian cancer. Further investigations of topotecan in ovarian cancer, including first-line use and combination with other active agents, are indicated.
42
Perez-Soler, R., F. V. Fossella, B. S. Glisson, J. S. Lee, W. K. Murphy, D. M. Shin, B. L. Kemp, et al. "Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy." Journal of Clinical Oncology 14, no. 2 (February 1996): 503–13. http://dx.doi.org/10.1200/jco.1996.14.2.503.
Full textAbstract:
PURPOSE This study was designed to assess the anti-tumor activity of topotecan (TPT) in patients with advanced non-small-cell lung cancer (NSCLC) previously untreated with chemotherapy. PATIENTS AND METHODS Patients with stage IIIB or IV NSCLC with measurable disease in nonradiated fields were eligible. Other eligibility criteria were Zubrod performance status (PS) < or = 2 and adequate renal and liver function. TPT was administered at a dose of 1.5 mg/m2/d for 5 days over 30 minutes every 21 days. Of 48 registered patients, 40 were fully assessable. Nineteen patients had adenocarcinoma (AD), 14 squamous carcinoma (SCC), and seven poorly differentiated carcinoma. RESULTS Six patients (15%) achieved a partial remission (PR) (durations: 8, 14, 18, 28, 56, and 61 weeks) and four patients a minor response; 10 patients had stable disease and 20 patients progressive disease. The PR rate was 36% (five of 14 patients) in patients with SCC versus 4% (one of 26 patients) in those with other histologies (P = .014). The overall median survival time was 38 weeks and 30% of patients were alive at 1 year. Grade 3 to 4 granulocytopenia and thrombocytopenia occurred after 76% and 10% of courses administered, respectively. No grade 3 to 4 nonhematologic toxicities were observed. Grade 1 or 2 nonhematologic toxicities consisted of nausea (46% and 5%), vomiting (31% and 7%), and fatigue (53% and 16%). CONCLUSION TPT at the dose and schedule used has moderate antitumor activity in NSCLC; its activity is mostly limited to patients with SCC. TPT is well tolerated, with myelosuppression of short duration being the most common and limiting toxicity.
43
Kishan, Amar U., Marguerite Tyran, Julius Weng, Shrinivasa Upadhyaya, James Lamb, Michael Steinberg, Christopher King, and Minsong Cao. "Stereotactic body radiotherapy to the prostate and pelvic lymph nodes: A detailed dosimetric analysis of a phase II prospective trial." British Journal of Radiology 92, no. 1099 (July 2019): 20181001. http://dx.doi.org/10.1259/bjr.20181001.
Full textAbstract:
Objective: To evaluate the dosimetric ramifications of simultaneously irradiating the prostate and pelvic lymph nodes (PLNs) with a stereotactic body radiotherapy approach based on rigid registration to intraprostatic markers (IPMs). Methods and materials: Nineteen patients received concurrent SBRT to the prostate and PLNs on a phase II clinical trial. The translational and rotation shifts required for rigid registration to bony anatomy and changes in bladder and rectal anatomy were compared between patients with > 90% and < 90% coverage of the nodal clinical target volume (CTVN ) as drawn on fractional kilovoltage cone-beam CTs. Stepwise multivariable regression models evaluated relationships between these anatomical parameters and the change in V100%CTVN. Results: The average V100%CTVN per patient was 92.4 % (IQR, 90.2 – 96.4 %). For five patients (26.3%), the average was 85.0 % (IQR, 82.4–88.3 %). The left-right and superior-inferior translational shifts, sagittal rotational shift, and change in bladder volume were significantly different ( p < 0.05 for all via Student’s t-test). Changes in bladder height, left/right shift, superior/inferior shift, 3-D shift, and axial rotation as significant predictors of change in dosing of V100%CTVN. Conclusion: While simultaneous SBRT to the prostate and PLNs based on rigid registration to IPMs provides adequate PLN coverage in most instances, overall coverage may be lower than anticipated if anatomy is unstable. Careful evaluation of bladder filling on kV-CBCT before treatment may be the most practical method for estimating accuracy prior to treatment. Advances in knowledge: Simultaneous SBRT to the prostate and PLNs based on rigid registration to IPMs provides adequate PLN coverage in most instances.
44
Gerber, C., P. Sirieiro, I. Nasser, C. Taber, and H. Miranda. "Postactivation potentiation improves jumps performance in children ages 6 to 8 years old." Archivos de Medicina del Deporte 38, no. 3 (June 21, 2021): 192–96. http://dx.doi.org/10.18176/archmeddeporte.00043.
Full textAbstract:
Introduction: The aim of the present study was to investigate the effects of postactivation potentiation (PAP) in vertical and horizontal jump performance in pre-pubertal children. Material and method: One hundred and nineteen children (65 girls and 54 boys; 6.8 ± 0.7 years old; 124.5 ± 6.4 cm; 25.2 ± 5.1 kg) participated in this study. This was a transversal cross-sectional study which incorporated a within-subjects repeatedmeasures design, where participants completed all protocols. The experimental procedure required four total testing, separated by one week, using a counterbalanced. This study investigated jumping performance associated with weighted jumps, lowload vertical jumps, and horizontal jumps. During two sessions the participants performed vertical jumps with and without PAP, the other two sessions the same procedures were performed for horizontal jumps. The PAP protocol consisted of one set of five weighted countermovement jumps with low-load (10% of body mass) and a rest interval of four minutes prior to the jump tests. Paired t-tests were used between conditions (PAP and control) in the vertical jump and horizontal jump test. In addition, Cohen’s d effect size and 95% confidence interval was used. Results: Significant jump height was observed in the vertical jump in the PAP condition compared to the control condition (p = 0.007). Similar results were observed for the horizontal jump tests, with significant longer distance observed in the PAP condition (p = 0.036). Conclusions: Pre-pubertal children can benefit from the effects of PAP in vertical and horizontal jumping performance when preceded by low-load ballistic movements. A protocol implementing low-loads, determined by a relative percentage of body mass is effective to promote PAP for young children.
45
Ji, Jie, Tian Dong, Pu Kuang, Zhigang Liu, Jiazhuo Liu, Li Zhang, Ting Niu, and Ting Liu. "Chidamide-Containing Conditioning Allogenic Hematopoietic Stem Cell Transplantation Improves Prognosis of Acute Lymphoblastic Leukemia with Pre-Transplant Response Less Than Complete Remission." Blood 132, Supplement 1 (November 29, 2018): 3366. http://dx.doi.org/10.1182/blood-2018-99-114763.
Full textAbstract:
Abstract Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative option currently offered to patients with high-risk or relapsed acute lymphoblastic leukemia (ALL). However, active disease or minimal residual disease (MRD) prior to HSCT is associated with early relapse and poor prognosis with long-term survival less than 30%. We have confirmed that chidamide, a selective histone deacetylase inhibitor (HDACi), work synergistically with cytotoxic agents such as combination of cladribine, gemcitabine and busulfan as conditioning therapy against lymphocytic malignancies. Here, we conducted a clinical trial to evaluate the efficacy of chidamide containing conditioning allo-HSCT in patients with these high-risk ALLs. Methods: Patients with active ALL or MRD received a myeloablative conditioning consisting of chidamide, fludarabine, cytarabine and busulfan (ChiFAB), followed by infusion of peripheral blood hematopoietic stem cells from related or unrelated donors. The ChiFAB was administered as following: chidamide was given orally at 20 mg twice weekly started from D-7 for 3 weeks; fludarabine was given intravenously at 30 mg/m2 D-6 to D-2; cytarabine was given 4 hours after the finish of fludarabine at 1 g/m2 D-6 to D-2; and busulfan was given intravenously once daily at 3.2 mg/kg D-6 to -3. Prophylaxis of acute graft-versus-host-disease were posttransplant cyclophosphamide plus cyclosporine for matched donor transplants, and additional post-transplant anti-thymocyte globulin and mycophenolate mofetil for haplo-HSCT. Donor lymphocyte infusion was not routinely administered in this trial. Results: Twenty-four patients were enrolled with median age of 24.5 (16-61 years). Male to female ratio was 3:1. Six (25%) had a diagnosis of Philadelphia positive acute B cell lymphoblastic leukemia (Ph+B-ALL), 8 (33.3%) had Ph-B-ALL, and 10 (41.7%) had T-ALL. Nineteen (79.2%) patients were MRD positive (blast cells <5% in the bone marrow), while five (20.8%) were with active disease (blast cells ≥5%). Eleven (45.8%) patients underwent matched sibling donor transplant, 4 (16.7%) underwent matched unrelated donor transplant, and 9 (37.5%) received haplo-HSCT. Neutrophils and platelets engrafted at a median of 14 days (12-20 days) and 16 days (12-46 days) post-transplant, respectively. Twenty (83.3%) patients reached MRD negative at 30 days. The median follow-up time of the whole cohort was 9.2 months (2-43.8), estimated 1-year progression free survival (PFS) and overall survival (OS) are 53.1% and 59.4% (Figure-1 A&B). For patients with MRD or active disease, estimated 1-year PFS are 67% and 0% (Figure-1 C), and estimated 1-year OS of these 2 groups of patients are 67.7% and 30% (Figure-1D), respectively. Only one patient (4.2%) developed II° aGvHD within 100 days post-transplant (Figure-1 E). The incidence of non-relapse mortality is 24.6% (Figure -1 F). Conclusions: Chidamide-containing conditioning allo-HSCT may improve the prognosis of ALL with MRD. Figure 1. Figure 1. Disclosures Liu: West China Hospital of Sichuan University: Employment.
46
Androulakis, Nikos, Charalambos Kourousis, Meletios A. Dimopoulos, George Samelis, Stelios Kakolyris, Nikos Tsavaris, Kostas Genatas, et al. "Treatment of Pancreatic Cancer With Docetaxel and Granulocyte Colony-Stimulating Factor: A Multicenter Phase II Study." Journal of Clinical Oncology 17, no. 6 (June 1999): 1779. http://dx.doi.org/10.1200/jco.1999.17.6.1779.
Full textAbstract:
PURPOSE: To determine the efficacy and tolerance of single-agent docetaxel and granulocyte colony-stimulating factor in patients with advanced pancreatic cancer. PATIENTS AND METHODS: Thirty-three chemotherapy-naive patients (median age, 65 years) with histologically confirmed pancreatic cancer were treated, after appropriate premedication, with docetaxel (100 mg/m2) and granulocyte colony-stimulating factor (150 μg/m2/d subcutaneously days 2 through 10) every 3 weeks. World Health Organization performance status was 0 to 1 in 28 patients (85%) and 2 in 5 patients (15%). Twenty-nine patients had stage III and IV disease. RESULTS: One complete response (3%) and one partial response (3%) were observed for an overall response rate of 6% (95% confidence interval, 2.1% to 14.2%). Nineteen patients (58%) had stable disease and 12 (36%) had progressive disease. The duration of the two objective responses was 10 and 28 weeks, and the median time to tumor progression was 20 weeks. The median overall survival was 36 weeks. The actuarial 1-year survival was 36.4%. The performance status improved in seven of 21 assessable patients (24%) and pain improved in 14 of 21 (67%) assessable patients; five patients (29%) experienced weight gain during treatment. Disease-related asthenia, anorexia, vomiting, and diarrhea improved in 29%, 15%, 67%, and 47% of the assessable patients, respectively. Serum concentrations of CA 19-9 were decreased by more than 50% in seven patients (35%). Grade 3 and 4 neutropenia occurred in four patients (12%) and eight patients (24%), respectively, with two episodes of febrile neutropenia. There were no treatment-related deaths. Grade 3/4 asthenia occurred in three patients. CONCLUSION: Although docetaxel has a marginal objective activity in pancreatic cancer, it seems to have an important effect on tumor growth control, conferring a clinical benefit.
47
Tiwari, Anand, Uma Karki, Kendra Norwood, Ja’Nia Johnson, and Lila B. Karki. "Legume-grass Pastures Enhanced the Performance of Kiko Does." Journal of Animal Science 99, Supplement_2 (May 1, 2021): 42–43. http://dx.doi.org/10.1093/jas/skab096.078.
Full textAbstract:
Abstract Inadequate and poor-quality pastures dominated with perennial grasses are one of the major reasons for poor performance of goats in the Southeastern United States. Legume addition to grass pastures may improve performance of goats. However, such information is not documented well. The objective of the study was to evaluate the impact of legume addition to pastures on goat performance. The study site consisted of 10 plots (average plot size: 0.44 ha). Five plots were sown to southern peas (Vigna unguiculata)-browntop millet (Urochloa ramosa) 50:50 mix) and remaining plots to sole browntop millet. Forage biomass samples were collected, dried, and weighed for dry matter (DM). Nineteen Kiko does (initial age: 15–16 months; live weight (LWt): 34 ± 1.4 kg) were divided into two groups: 10 to legume-grass plots and nine to grass-only plots; allocation of does to either group was based on their initial LWt, FAMACHA (5-color card) score (1–5: 1–2 – not anemic, 4–5 anemic), and body condition score (BCS: 1–5, 1 extremely lean, 5 obese) to create uniform groups. Does were rotationally stocked based on available forages in their respective plots for 87 days starting mid-August 2020. Does’ LWt, FAMACHA score, and BCS were collected just before they were deployed to research plots, in every 14 d during the study, and at the end. Forage dry-matter data and animal-performance data were analyzed using Mixed and GLM procedures, respectively, in SAS 9.4. Legume-grass and grass-only plots yielded similar DM. Does in legume-grass group gained more weight (37.4 ± 0.50 kg vs. 35.7 ± 0.53 kg; P = 0.0209) and better FAMACHA score (2.1 ± 0.06 vs. 2.4 ± 0.07; P = 0.0044) and BCS (2.6 ± 0.02 vs. 2.5 ± 0.03; P = 0.0008) versus grass group. Results showed that legume-grass-mixed pastures promote the performance of growing does than sole-grass pastures.
48
Barnes, H. M. "Seventy-five Years of Research in Wood Preservation and Deterioration." Forest Products Journal 70, no. 4 (November 1, 2020): 476–81. http://dx.doi.org/10.13073/fpj-d-20-00055.
Full textAbstract:
Abstract Seventy-five years of research in wood protection at the Forest Products Lab at Mississippi State University are described. A history of wood protection is presented along with an overview of the facilities supporting the research. Program objectives are presented along with the personnel responsible for building the program. A brief presentation of research areas is given followed by some program metrics.
49
Jiang, Qian, Xiao Jun Huang, Kaiyan Liu, Huan Chen, Yuhong Chen, Zhiyong Cao, and Daopei Lu. "Subclinical Alterations in Coagulation in Patients during Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation." Blood 106, no. 11 (November 16, 2005): 5292. http://dx.doi.org/10.1182/blood.v106.11.5292.5292.
Full textAbstract:
Abstract Objective To evaluate the alterations in coagulation in patients during modified busulfan plus cyclophosphamide (BUCY) ± antithymocyte globulin (ATG) before allogeneic hematopoietic stem cell transplantation (allo-HSCT), and to assess the effect of ATG on coagulation system as part of conditioning regimen. Methods Thirty-five patients with various hematological malignancies undergoing allo-HSCT were assessed. Nineteen patients from HLA-identical siblings (group A) were conditioned with modified BUCY regimen, included cytarabine (2g/m2 i.v., day -9), busulfan (4mg/kg p.o. in divided doses daily, day -8 to day -6), cyclophosphamide (1.8g/m2 i.v., day -5 and day -4) and Me-CCNU (250mg/ m2 p.o., day -3). Sixteen patients from HLA-mismatched family members or HLA-matched unreleated donors (group B) were conditioned with modified BUCY + ATG regimen, added cytarabine (4g/m2 i.v., day -10 and -9) and rabbit ATG (2.5mg/kg i.v., day -5 to day -2, SangStat S.A.S., France). Blood samples were obtained before the start of regimen until day +1 after allo-HSCT. The following laboratory parameters were measured: prothrombin time (PT), active partial thromboplastin time (APTT), Fgrinogen (Fg), antithrombin (AT), D-Dimer, Fgrin degradation product (FDP), platelet (PLT), liver enzymes and bilirubin. VIII:C, IX:C, XI:C and XII:C in some blood samples with prolonged APTT were determined. Clinical hemorrhagic symptoms were monitored. Results From day -5 of conditioning regimens, temporary lengthening of APTT, which peaked on day -3, occurred in 16/19 (84.2%) patients in group A and 19/19 (100%) patients in group B, continued rise in Fg occurred in 17/19 (89.5%) patients in group A and 19/19 (100%) patients in group B, a progressive decrease of PLT was observed in all patients of two groups. Alterations of Fg and PLT were more significant in group B compared to those in group A. Transient D-Dimer increase was detected only in group B on day -3. Among intrinsic pathway coagulation factors, XII:C and XI:C were decreased commonly and significantly when APTT was prolonged. No difference between the two groups could be found with regard to PT, FDP, AT and liver parameters which remained nearly in normal ranges. Most of patients in two groups did not have overt bleeding manifestations. Conclusions Modified BUCY ± ATG conditioning regimen can induce subclinical alterations in coagulation. The regimen contained ATG has more significant effect on coagulation parameters.
50
Xian, Rena R., Genevieve M. Crane, Lisa M. Haley, Christopher D. Gocke, Ming-Tseh Lin, Aparna Pallavajjalla, Michael J. Borowitz, Lode J. Swinnen, and Amy S. Duffield. "Late-Relapse Diffuse Large B-Cell Lymphoma Frequently Represents Recurrence of the Original Disease, and Demonstrates Evidence of Superimposed Clonal Heterogeneity and Clonal Evolution." Blood 124, no. 21 (December 6, 2014): 2955. http://dx.doi.org/10.1182/blood.v124.21.2955.2955.
Full textAbstract:
Abstract BACKGROUND: Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma. While most relapses occur within 2 years, a small proportion of patients present with late relapse (LR) after 5 years. As there are very few studies addressing the pathobiology of LR-DLBCL, the aim of this study is to further characterize the clinical, pathologic and molecular features of these neoplasms. METHODS: A retrospective analysis of all patients with DLBCL treated at Johns Hopkins Hospital between 1984 and 2013 was performed. Patients with low-grade lymphoma at any time-point were excluded. Disease-free intervals (DFI) of 5 years or greater were designated as LR. Five paired diagnostic (D) and relapse (R) samples were available for further studies. DNA was extracted from formalin fixed paraffin embedded tissue. IGH gene rearrangement status was determined by PCR. SNP microarray was performed, and copy number variations (CNV) were defined as loss or gain of signal over at least 2 megabases. Targeted next generation sequencing (NGS) using a cancer hotspot panel was also performed. Variant calls were generated using Torrent variant caller and a laboratory-developed analysis pipeline. RESULTS: One hundred thirty-three patients with relapsed DLBCL were identified. Forty-three (32.3%) patients were diagnosed in the pre-rituximab era. One hundred fourteen (85.7%) patients had early relapse (ER) with 99 (74.4%) patients recurring within 2 years. Nineteen (14.3%) patients had LR (mean 7.9 years; median 7.3 years; up to 15.6 years). There were no significant differences in age at diagnosis, race, staging marrow status, or overall survival (OS) in ER versus LR patients. Extra-nodal presentation at diagnosis (89.5% vs. 65.8%; p = 0.04) and extra-nodal-only disease over time (73.7% vs. 48.2%; p = 0.04) were more common in LR cases. Both groups had similar rates of recurring at a different site from the original disease (79.3% vs. 89.5%; p = 0.30). Table 1. Molecular profile of paired D and R DLBCL Patient IGH clonality comparison (D vs. R) Clonal Heterogeneity (D / R) Total CNVs (D / R) Shared CNVs Unique CNVs (% of D / % of R) 1 Same + / + 24 / 21 15 37.5 / 28.6 2 Same + / + 15 / 32 11 26.7 / 65.6 3 Same + / + 32 / 15 7 78.1 / 53.3 4 2 in D / 1 persists in R + / + 8 / 20 1 87.5 / 95.0 5 Different - / + 4 / 5 0 100 / 100 The average DFI was 7.1 years in the 5 LR patients selected for additional studies. IGH gene rearrangement analysis demonstrated identical D and R IGH clones in 3 cases (Table 1). Patient 4 showed 2 rearranged alleles at D with only 1 persisting at R. Patient 5 had lymphomas with unique IGH rearrangements. SNP microarray data demonstrated the presence of clonal heterogeneity in all but 1 sample (4 of 5 at D; 5 of 5 at R). Among the 4 patients with clonally related IGH gene rearrangements, there was only partial overlap in CNVs (approximately 40% on average) between the D and R lymphomas. The average CNVs was similar in the D and R samples (16.6 vs. 18.6 respectively; p = 0.75). Chromosomes 2, 3, 6, 9, and 17 were frequently altered, and CNVs involving the BCL-6, CDKN2A, TP53, and MYC loci were also commonly seen; but there was no systematic difference between the CNVs identified at D and R. NGS showed a variety of mutations, but no consistent pattern of mutations acquired at R. There was a nonsense mutation in exon 2 of CDKN2A in the R sample in patient 1, and both D and R samples showed the same copy-neutral loss-of-heterozygosity of 9p encompassing the CDKN2A gene. In addition, missense mutations of TP53 were detected in patients 4 (only at R) and 5 (only at D). CONCLUSIONS: This study demonstrates that LR-DLBCL is an uncommon phenomenon with most cases representing recurrence of the original disease. LR patients have similar OS as ER patients, and the only clinical factors segregating LR from ER are higher rates of extra-nodal presentation and extra-nodal-only sites of disease. Although most paired D and R cases share IGH clones, there is clear evidence of clonal heterogeneity with clonal evolution over time. This suggests that DLBCL may contain minor subclones not susceptible to chemotherapy, which persist subclinically acquiring additional mutations over time eventually generating clinically-evident relapse. In rare cases, the late “relapse” may occur as an unrelated lymphoma that arises spontaneously or secondary to the mutagenic effects of chemotherapy. The precise mechanism of this long latency is yet unclear, and requires further investigation. Disclosures Borowitz: Becton Dickinson Biosciences: Research Funding.